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SUMMARY 
BR-16A is a herbal preparation with severalputative psychotropic effects. Recentworkhas suggestedthatitfacilities 
certain aspects of cognition and that it ameliorates ECT-induced amnesia in animal models. The present study 
sought to assess whether it affects noradrenergic and dopam inergicfunctioning in the central nervous system. A dult 
male Sprague-Dawley rats received BR-16A (200mg/kg) or vehicle for one month. The animals were subsequently 
challenged with clonidine (100 mg/kg I.P.), apomorphine (2mg/kg I.P.), or saline in a factorial design, and motility 
of the animals was immediately thereafter assessed using a small open field. BR-16A neither attenuatedclonidine-
induced alpha-2 noradrenergic receptor-mediated hypomotility nor accentuated apomorphine-induced dopamine 
postsynaptic receptor-mediated hypermotility, suggesting that it does not interfere with alpha-2 noradrenergic and 
dopamine postsynaptic receptor functioning. 
INTRODUCTION 
BR-16A (Mentat: Himalaya Drug Company) is a 
herbal preparation derived from India's rich culture in 
traditional medicine. BR-16A contains Jal-brahmi 
(Bacopa monnieri), Mandookaparni (Centella asiatica), 
Ashwagandha (Withania somnifera), Shankapushpi 
(Evolvulusalsinoides),Jatarnansi(Nardostachysjataman-
si), Vach (Acorusm calamus), all of which are claimed to 
improve memory functions; other ingredients include 
Tagar (Valeriana wallachii), Badam (Prunus amyodalus), 
Salap (Orchis mascula), Lavang (Syzyoium aromaticum) 
and Pearl (Mukta pishti), which are claimed to be nerve 
tonics; all other ingredients are putative general tonics and 
vitalizers (Himalaya Drug Co., 1991; Satyavati, 1993). 
Recent research has found BR-16A to improve several 
cognitive - particularly memory - functions. Agrawal et al 
(1990a & b) reported that BR-16A improves memory 
parameters and decreases anxiety parameters in normal 
volunteers. Verma and Kulkarni (1991) observed that 
BR-16A reduces scopolamine-induced delay in transfer 
latency in rats tested in an elevated plus maze. Kulkarni 
and Verma (1992a) found that BR-16A attenuates acute 
and chronic ECT-induced retrograde amnesia in rats tested 
with a passive avoidance paradigm. Joseph et al (1993) 
and Andrade et al (1993) found BR-16A to protect against 
the development of ECT-induced anterograde amnesia in 
rats tested in a complex maze and in a 'T' maze using a 
reward oriented paradigm. 
Considering these various central nervous system ef-
fects of BR-16A, it seemed reasonable to expect that this 
preparation influences neuroceptor functioning. The 
present study therefore addressed the possible effects of 
BR-16A on alpha-2 noradrenergic and dopamine post-
synaptic receptor functioning in the rat brain using chemi-
cal neuroreceptor agonists challenges in vivo. 
MATERIAL AND METHODS 
Adult, male, Sprague-Dawley rats, housed four per 
cage with free access to tap water and standard laboratory 
diet, received either BR-16A (Himalaya Drug Company) 
in a dose of 200mg/Ml/Kg or vehicle (distilled water) 
alone once daily for one month. To ensure accurate dosing, 
intragastric administration of BR-16A/vehicle was 
adopted. 
The animals were then parenterally challenged with 
clonidine (Sigma Chemicals; 100 mg/ml/kg i .p.), apomor-
phine (Sigma Chemicals; 2 mg/ml/kg i.p.) or saline (1 
ml/kg i.p.) in a factorial design with BR-16A/vehicle as 
one factor and neuroreceptor challenge/saline as the other 
factor. 
In the administered dose, clonidine is an alpha-2 
adrenoceptor agonist which induces hypomotility while 
apomorphine is a dopamine postsynaptic receptor agonist 
which induces hypermotility. (Andrade et al, 1990; 
Andrade & Pradhan, 1991). 
In effect, therefore, there were two factorial design 
experiments: one with clonidine for alpha-2 adrenoceptor 
effects, and the other with apomorphine for dopamine 
postsynaptic receptor effects. In each of the two experi-
ments there were 4 groups: BR-16A + Neuroreceptor 
agonist, BR-16A + saline, vehicle + neuroreceptor agonist 
and vehicle + saline. Vehicle-treated rats served as con-
trols to the BR-16A-treated group. Saline-injected rats 
served as internal controls to the neuroreceptor agonist-
challenged animals; the internal controls were necessary 
to control for perturbations induced by BR-16A in non-
adrenergic/dopaminergic neurotransmitter systems. 
Immediately after the injection, the animal was placed 
in a glass cylinder measuring 22 cm in internal diameter 
and 45 cm in height. Three minutes were allowed for the 
animal to adapt to the stress of being handled, and to the 
new environment. Motility of the animal was then 
recorded as number of quadrants (marked off on the floor 
of the cylinder) crossed by the animal during a 3 minute 
period. The procedure followed is the one described for 
the small open field (Van Ree& De Wied, 1988). Monitor-
ing was conducted between 10 am and 2 pm only (to 
control for diurnal variations in motility) in a disturbance 
free environment, by an experienced rater who was blind 
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to the experimental status of the rats. Data were analyzed 
using Two Way Analysis of Variance. 
RESULTS 
Table 1 
Mean motility scores in BR-16A and vehicle treated rats injected 
with clonidine (100 wg/kg i.p.) or saline (n=10/cell). 
BR-16A  Vehicle 
Clonidine 
Saline 
1.0 
8.6 
(0.82) 
(1.35) 
0.6 (0.7) 
9.5 (2.07) 
Main effect for BR-16A vs vehicle :NS 
Main effect for clonidine challenge :p <0.0001 
Challenge x BR-16A/vehide interaction :NS 
Table 2 
Mean motility scores in BR-16A and vehicle treated rats injected 
with apomorphine (2 mg/kg i.p.) or saline (n=11/cell). 
BR-16A  Vehicle 
Apomorphine 
Saline 
26.5 
5.0 
(32) 
(2.1) 
27.6 (5.3) 
7.4 (4.8) 
Main effect for BR- 16A vs vehicle :NS 
Main effect for apomorphine challenge :p <0.0001 
Challenge x BR-16A/veNcle interaction :NS 
Figures in parenthesis indicate Standard Deviation. 
The M ± SD motility scores of BR-16A and vehicle 
treated rats injected with clonidine or with apomorphine 
are presented in Tables 1 and 2 respectively. The main 
effect for BR-16A/vehicle and the BR-16A/vehicle X 
receptor challenge interaction were not significant in both 
clonidine and apomorphine experiments. The main effects 
for clonidine (F 1.36 = 375.23, p <0.0001) and apomor-
phine (F 1.40 = 290.69, p <0.0001) were however both 
significant, testifying to the known effects of these drugs 
on motility. 
DISCUSSION 
The absence of a significant main effect for BR-
16A/vehicle indicates that Br-16A exerts no effect on 
animal motility independent of the neurotransmitter sys-
tems challenged. The absence of a significant BR-
16A/vehicte x receptor challenge interaction indicates that 
BR>16A exerts no effect on motility specific to the 
neurotransmitter system challenged. 
Expressed otherwise, BR-16A does not alter alpha-2 
adrenoreceptor and dopamine postsynaptic receptor 
functioning. Since these neuroreceptors are sensitive to 
psychotropic drug induced changes in the respective 
neurotransmitter systems, it seems likely that BR-16A has 
neither adrenergic not dopaminergic effects. 
These findings eliminate two possible mechanisms of 
action of Br-16A. These findings also suggest that BR-
16A will not interfere with functioning in these two 
neurotransmitter systems, occasioning adverse effects 
mediated by these receptors much as is observed with 
psychotropic drugs such as neuroleptics and tricyclic an-
tidepressants. Scope exists for the investigation of 
cholinergic and opioid peptidergic effects of BR-16A, as 
evidenced by the preliminary work of Kulkarni and Verma 
(1992 a &b). 
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